What are the Treatment Options for HER2-Positive Cancers?
The treatment landscape for HER2-positive cancers has evolved significantly with the development of targeted therapies. Some of the most commonly used HER2-targeted therapies include:
Trastuzumab (Herceptin): A monoclonal antibody that binds to the HER2 protein, inhibiting its activity. Pertuzumab (Perjeta): Another monoclonal antibody that prevents HER2 from dimerizing with other HER receptors, thereby blocking signaling pathways that promote tumor growth. Ado-trastuzumab emtansine (T-DM1, Kadcyla): An antibody-drug conjugate that combines trastuzumab with a chemotherapy agent to deliver targeted treatment to HER2-positive cells. Lapatinib (Tykerb): A small molecule tyrosine kinase inhibitor that blocks the intracellular signaling pathways of HER2.
